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Abstract
Purpose Numerous studies have examined non-adherence to adjuvant endocrine therapy in women recovering from breast
cancer, but none provides a comprehensive theory to explain the challenges of long-termmedication taking and resilience needed
to continue. The aim of this study was to source, appraise, and synthesize data from existing qualitative studies to develop an in-
depth explanatory model of non-adherence and discontinuation of hormonal medication among breast cancer survivors.
Methods A comprehensive search of databases and the literature identified 24 eligible qualitative studies published 2010–2019.
Quotations (n = 801) listed within these papers and the original author interpretations were synthesized using NVivo, and
grounded theory methodology.
Results At the beginning, knowledge about adjuvant endocrine therapy, trust in doctors, and worries and expectations, mean
agreeing to medication is the only viable option, akin to a Hobson’s choice. Thereafter, women’s ability to deal with medication
side-effects, knowledge and support received affect their decision to continue, akin to a horned dilemma where giving up the
medication risks cancer recurrence and continuing means reduced contentment. Women stopping medication altogether question
treatment necessity, search for normalcy and prioritize quality of life.
Conclusion Shared experiences and understandings were uncovered by examining commonalities in existing publications. The
core category explained the difficulties women face with the initial decision to accept long-term endocrine therapy and then the
everyday challenges of continuing or deciding to stop treatment early. An educational tool to inform survivors and health
professionals about these challenges could potentially improve women’s experience on treatment and in turn their adherence.
Keywords Adherence, antineoplastic agents, hormonal . Systematic review . Grounded theory . Qualitative research . Breast
neoplasms
Background
Breast cancer is the most common type of cancer in women
across the world, albeit with a lower incidence in most of the
developing regions (age-standardized at below 50 per 100,000),
compared with Western Europe (92.6 per 100,000) or North
America (84.8 per 100,000) [1]. However, improvements in
screening, early diagnosis and treatment in higher-income re-
gions have resulted in a continued fall in death rates from breast
cancer in some countries such that the 2019 annual breast cancer
age-standardized death rate in North America was estimated to
be 12.6 per 100,000 and in the EU 13.36 per 100,000 [2]. For
comparison, this mortality statistic is 15.5 per 100,000 in Central
and Eastern Europe, 18.4 in Northern Africa, and 21.6 in
Polynesia [1]. Improvements in treatment include the use of
long-term endocrine therapy (ET) in hormone receptor (HR)
positive cases, which account for two-thirds of all breast cancer
diagnoses [3]. Prescribing ET, i.e. tamoxifen or an aromatase
inhibitor to take bymouth, as adjuvant treatment after surgery or
radiation therapy reduces cancer recurrence and mortality rates
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[4, 5]. However, research consistently shows challenges for
some women to fully adhere to their course of ET [6].
Adherence is defined as ‘the extent to which a person’s
behaviour corresponds with agreed recommendations from a
health care provider’ [7]. According to guidelines, ET as ad-
juvant treatment for breast cancer should be taken for at least
5 years [8] with studies showing even better results when used
for 10 years [9, 10]. However, the literature shows variation in
adherence to ET in breast cancer, with studies reporting ad-
herence to range from 41 to 72%, with early discontinuation
of 5-year courses being 31 to 73% [11]. Rather than being
static, it appears that adherence to ET decreases over time
going from 90% in the first year to 77% in the third and
51% in the fifth years [12]. This is despite knowing that low
adherence to ET is associated with an increase in all-cause
mortality [13], while longer adherence periods lower the risk
of mortality and recurrence [12]. Thus non-adherence to ET,
like in many other conditions, appears to be a complex prob-
lem which is worthy of further exploration with in-depth, in-
terpretive approaches [14].
Although multiple qualitative studies have been undertaken
to understand and describe women’s perceptions and experi-
ences of a breast cancer diagnosis and its treatment in different
global settings, none provides a comprehensive theory to ex-
plain all the challenges of long-term medication-taking in HR-
positive cases and the resilience needed to continue. In addition,
no secondary research has collected, compared and analysed
these different studies to develop an all-encompassing theoreti-
cal insight of a phenomenon which may well have experiential
universality, justifying a review of the global literature. The
purpose of this qualitative systematic review and meta-
synthesis then was to source, appraise and synthesize data from
existing qualitative studies to develop an in-depth explanatory
model of non-adherence with ET in breast cancer survivorship
across the world. The aim was to use a grounded theory (GT)
and an interpretivist approach. GT was chosen as the method of
analysis so that the findings could meaningfully feed into the
next phase of investigations; an interview study which itself
aimed to use GT. GT has its roots in sociology and is based
on the notion that concepts grounded in the data can be exam-
ined and integrated into a core category [15]. The interpretivist
approach is concerned with deconstructing the meanings of the
phenomenon being researched in order to explain why it
operates the way it does [16].
Methods
Data retrieval, abstraction and appraisal
This was a systematic review and meta-synthesis of the
qualitative literature using grounded theory. A comprehen-
sive search of the published literature was completed via
multiple relevant databases to identify qualitative research
papers on the topic of women’s adherence to oral ET in
breast cancer, namely, PubMed, Web of Science,
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PsycINFO, Wiley Online Library and
ProQuest. In addition, Google scholar, Taylor & Francis
online, ScienceDirect and SpringerLink were searched to
identify studies that may not have been indexed in the pre-
vious databases. The references in the identified articles
were also scanned for relevant studies that may have been
missed in the database searches. The search was conducted
by the first author (OA) and verified by the third (PD). The
searching began on 01/11/2017 and a final check took place
on 23/01/2020.
Articles were included if they were primary research stud-
ies, used qualitative methodology, investigated adherence to
adjuvant ET in the management of HR-positive breast can-
cer and were written in the English language. We included
papers published in the decade 2010–2019 reasoning this era
would provide data most relevant to modern practice.
Studies were excluded if not written in English, used quan-
titative methodology, were reviews, were not specifically
about breast cancer or did not investigate adherence to ET.
A full search history is detailed in the Online Resources 1, 2,
3, 4, 5, 6, showing the construction of the search queries, the
narrowing down of the searches and the final yield from
each database. The articles yielded from each database were
then reviewed by the first author (OA) who read the titles
and abstracts of each and collected all potentially relevant
articles for discussion with the third author (PD). Both au-
thors applied the inclusion and exclusion criteria to this pool
of potentially eligible articles to finalize the list of included
articles. A grid was created to summarize the 24 included
studies (Online Resource 7).
Study quality was evaluated by the first author (OA) and
compared with an independent evaluation by the second (NP)
(with a discussion to resolve any differences) using criteria
based on the work of Hawker et al. [17]. The appraisal in-
volved using nine items on a checklist to assess the quality
of different elements of each paper, rating them as good (g),
fair (f), poor (p) or very poor (vp) (Online Resource 8). The
inter-rater reliability was not recorded, but there were less than
10 minor disagreements (i.e. where the criteria selected were
in close agreement—e.g. good vs fair) between the evaluators
from a total of 216 possible ratings. Hawker et al.’s [17] tool
was designed to provide insight into study strengths and
weaknesses rather than offering a cut-off for exclusion of
evaluated studies. The quality of the studies included in this
review varied but none was deemed to be of poor quality that
would render their findings meaningless. This paper’s compli-
ance with the ‘Enhancing transparency in reporting the syn-
thesis of qualitative research’ (ENTREQ) criteria is shown in
Online Resource 9.
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Data analysis
The first author (OA) completed data analysis in consultation
with the third (PD) who provided guidance and supervision.
Despite publications covering the topic generally [18, 19], on
closer scrutiny, no guidance detailed how to undertake a GT
synthesis of data using existing publications as the data
source. The authors therefore shaped their own methodology,
drawing heavily on the work of Atkins et al. (2008) [20] for
the data extraction elements and using previous GT expertise
for the detailed data analysis [21, 22].
The aim was to deconstruct the findings of the retrieved
studies in order to reconstruct them within a GT framework.
To do this, using the method of Atkins (2008), the studies
were read in detail first. Then all of the participant quotes
evidenced within the original studies (including those from
supplementary materials and appendices) from women relay-
ing their experiences with ET following the initial treatment of
their breast cancer were identified. Then every one of these
quotes were extracted to form a new dataset of quotes (within
the retrieved studies) using the software MindManager® (v.
2018). This software was chosen because each page allows a
limitless set of quotes to be displayed, minimized and
rearranged in interconnected or distinct mind-maps.
The analysis began by identifying first order constructs
relating to these quotes. Our approach was to firstly decon-
struct the findings of the retrieved studies within a grounded
theory (GT) framework. To do this, we devised a step-by-step
plan on how to organize and deal with the dataset. Thus the
quotes were organized along a treatment timeline in
MindManager®, to span experiences from receiving the initial
prescription, to treatment continuation and to treatment cessa-
tion. Ambiguous quotes were excluded. An example of an
ambiguous quote is “No one but God will discuss death with
me. Only God cares for my spirit.”, because it could not be
associated directly with a specific element of the treatment.
The process of analysis was to interpret each quote, making
detailed memos and asking questions such as _“what is going
on here?”, “Why?”, “How?” and “Where?”, to generate first-
order concepts for all the quotes. These concepts were then
grouped under higher-level criteria accompanied by writing
detailed criteria for each category. To minimize the impact
of preconceptions, the researcher (OA) wrote his own inter-
pretation of each quote without reference to the original paper.
He then compared his interpretations against the original au-
thors’ which offered further explanation and context. This
allowed the creation of novel constructs that were informed
by interpretations made by the original authors, creating new
superordinate groupings.
Quotations and interpretations were then transferred to the
NVivo software (v11) and further analyzed using open, axial
and selective coding in line with GT methodology to develop
the categories [15]. This involved brainstorming, questioning
the data, making constant comparisons (which contained
some deductive elements), thinking reflectively and using in-
ductive coding, as well as making diagrams to show the links
and the flow of the process under investigation. A paradigm
model was used which was composed of causal conditions
(the circumstances or events resulting in the phenomenon),
actions/interactions (activities directed toward the phenome-
non), consequences (the outcome of the actions/interactions)
and mediating factors (the conditions that affect the actions/
interactions). These were mapped for each of the categories by
posing statements in the form of “If this happens, I do this in
the anticipation that thiswill happen”. Finally, an overarching
theoretical scheme was created to interrelate the categories
within one core category to conceptually encompass and ex-
plain the collective experiences of the participants of the re-
trieved studies. The measures taken to ensure rigour and trust-
worthiness included prolonged engagement with the data, de-
scription of the study procedures and detailed audit trails.
Results
A total number of 582 papers were first identified narrowed to
447 with duplicates removed. The titles and abstracts of these
447 papers were reviewed for eligibility. A total of 81 papers
were included in the full-texted assessment, from which 57
papers were excluded, meaning 24 articles were selected for
qualitative synthesis (Fig. 1). There were a total of 801 quotes,
with 169 for the phase receiving the initial prescription, 506
for treatment continuation (n = 506) and 87 for treatment ces-
sation, with 39 ambiguous quotes. Three main categories,
explaining women’s adherence to ET in breast cancer survi-
vorship as conceived by the participants of the studies includ-
ed in the meta-synthesis are described below. The core cate-
gory ‘Hobson’s choice or a horned dilemma?’ encapsulates
the findings and provides an all-encompassing GT of the chal-
lenges of long-termmedication taking and the resilience need-
ed to continue (See Fig. 2). Hobson’s choice depicts a ‘free
choice’where in reality only one option is offered without any
alternatives [23]; a horned dilemma is about facing two equal-
ly problematic options whereby choosing either leaves you,
metaphorically, impaled by your own decision [24].
Core category ‘Hobson’s choice or a horned dilemma?’
At the start of treatment, when women sign up to long-term
ET, they do so without feeling that they have a real choice.
They are concerned about the recurrence of cancer, and
believe in the necessity of the treatment, leaving them with
no basis to decline. This is akin to Hobson’s choice—there
is no viable alternative. This interpretation of the situation
helps many women continue to take the medication for the
full duration of treatment. On the other hand, some women
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think of adhering to their ET as a horned dilemma. They
fear the treatment and its potential side-effects or have ex-
perienced the severe side-effects, leaving them confronted
with two equally bad options. There is the choice to contin-
ue but experience the side-effects and there is the choice to
stop but worry about cancer recurrence. This leaves women
constantly questioning whether they should continue ET
and work through the side-effects or stop and risk the return
of cancer. This is akin to a horned dilemma—women face
two equally problematic options. Those who choose to stop
ET reconcile their worries by accepting their life’s
impermanence.
The model shows the three main categories, their mediating factors and their interrelationship to explain medication non-adherence and 
discontinuation in breast cancer survivorship.
Guided by the 
doctors: 
accepting the 
long-term 
prescription
Knowledge 
about the 
treatment 
Trust in 
healthcare 
providers
Worries and 
expectations
Balancing 
priorities: 
adhering to the 
long-term 
treatment
Receiving 
support 
throughout 
treatment
Ability to 
deal with the 
side-effects
Knowledge 
about the 
treatment
Taking a 
chance: 
stopping the 
treatment early
Beliefs about 
treatment 
necessity
Precedence 
of quality of 
life over 
longevity
Continuous 
search for 
normalcy
A horned dilemma
Finishing the 
treatment
Deferring the 
treatment
Refusing the 
treatment
Consultation 
about adjuvant 
endocrine 
therapy
Hobson’s choice
Fig. 2 Representation of the core category ‘Hobson’s choice or a horned dilemma’
Fig. 1 Database searches and
article retrieval. Note. 366 records
were excluded at screening and
57 records at full-text analysis
because they were not primary
studies, did not use qualitative
methods or did not provide data
on hormonal therapy in breast
cancer.
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Theoretical category 1: guided by the doctors –
accepting the long-term prescription
Women with breast cancer are initially treated with surgery,
radiotherapy and/or chemotherapy, depending on their diag-
nosis. After this, those eligible are prescribed tamoxifen or an
aromatase inhibitor as ET to take long term, essentially to
prevent recurrence. The first step in the long-term manage-
ment of HR-positive breast cancer is therefore the prescription
of the ET (see Table 1). The causal condition, the actions/
interactions, the consequences and the mediating factors for
this first category are detailed here. For all the extracts refer-
enced within the text below, see Online Resource 10.
Causal conditions Women are asked to start ET immediately
but transitioning to this is not straightforward. Some can feel
overwhelmed by the information being given to them all at
once (Online Resource 10, extract 1), while having to manage
the fear of recurrence and worry about the possible side-
effects of the new medication (extracts 2 and 3). Altogether,
the data highlight women’s need for more specific information
about their condition and its treatment at this stage, fundamen-
tally because they are uncertain about the need for further
treatment. Women can feel vulnerable and emotionally unset-
tled especially as the acute stage of treatment would have been
difficult on a physical and/or psychological level. Some wom-
en need a gap before immediately transitioning to a new treat-
ment stage (extract 4).
Actions/interactions Accepting ET or delaying the start is in-
fluenced by a range of factors, for example, trusting the
healthcare provider, having stable and supportive family or
friends, own emotional and psychological stability, the pres-
ence of comorbidities and a desire to continue living cancer
free (extract 4). At this juncture, women are also obliged to
take on a greater level of responsibility for their own care. This
results in fewer hospital visits, and less frequent communica-
tion with healthcare providers, with some finding this shift
difficult to adjust to. Some look elsewhere for information
they have not been able to obtain from the health profes-
sionals. Women want, for example, the newest information
about their treatment, the latest clinical trials, published stud-
ies about breast cancer and information on the medication they
are about to use (extract 6).
Consequences The main consequence here is acceptance of the
first prescription, albeit for some with a delay. While women
who view ET as a necessity for the overall success of their
treatment proceed to long-term management with relative ease,
others defer the start until, for example, they regain personal
control over their life (extract 7). Women who seek information
about their condition and treatment from other sources find this
on specialist websites, forums and through other patients; the Ta
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risk is being misinformed about the medication. There is a no-
table transition on starting long-term treatment. Those who feel
well-informed report finding it easier to adapt, accepting the
treatment and taking care of themselves (extract 8).
Mediating factors Women’s trust in their healthcare provider,
their knowledge about the treatment and worries and expecta-
tions facilitate or constrain the process of accepting the ET.
Category 2: balancing priorities – adhering to the
long-term treatment
ET should be taken for 5 years or more, so when treatment
begins, the onus is on the woman to adhere to the regimen by
taking the medication by mouth every day. Certainly women’s
views about their treatment and its side-effects influence their
adherence, but these can change during the treatment period
(see Table 2).
Causal conditions Some women believe in the preventative
potency of their medication, despite the prospect of side-ef-
fects, deciding therefore to adhere at all costs. Others adhere
even if not fully convinced, to prevent regret (extract 9).
Knowledge about the treatment and its side-effects is an im-
portant factor at the start, but women are also surprised by the
severity of the side-effects when they experience them, ex-
pressing that better information in advance might have better
prepared them—others are taken aback despite having been
pre-warned. Healthcare providers are criticized for not fully
conveying the side-effects in advance (extract 10). Women
also worry specifically about the prospect of hitherto un-
known long-term effects, questioning the balance of risk ver-
sus benefit and whether persistence is worthwhile.
Paradoxically, while most women need information to better
adhere, too much knowledge can create an additional psycho-
logical burden (extract 11). A range of side-effects are men-
tioned in the data from physical to psychological (extract 12).
A strong factor is the availability and ease of access to
professional support. Lack of access to cancer specialists at
this stage leaves women feeling unsupported, having to de-
code experiences on their own. Some like consulting their GP
while others do not, believing GPs lack the knowledge and/or
desire to deal with breast-cancer-related issues. Pharmacists
might not be a natural point of contact either (extract 13).
Those who have a good relationship with healthcare providers
want to adhere to their advice; not seeing the same physician
during visits can thus be problematic (extract 14). Support
from other people including family members, friends and
co-workers is also important. Some especially benefit from
contacting other patients, who will better understand their pre-
dicament. Women who have a good relationship with loved
ones, receiving their support and encouragement, report ad-
hering to their treatment, while those lacking this support
report difficulties managing treatment and side-effects. The
presence of important others is a strong motivation to stay
well (extract 15), and women who feel they owe it to others
to continue living, adhere to treatment (extract 16). A barrier
to medication taking relates to costs and health insurance in
certain cases which women have to overcome (extract 17).
Actions/interactions Women who want to take their medica-
tion change their habits or incorporate their medication in their
daily routine (extract 18). With the need for support being an
important causal condition, womenmake a point of seeking the
help and encouragement appropriate for them (extract 19).
Women look to their healthcare providers for specific informa-
tion, but soon turn to other sources if not satisfied with the
answers given.While many look for specific information, some
simply want reassurance (extract 20). Women experiencing
side-effects look for ways to manage them, with varying levels
of success. Some take additional medications while others are
advised to change their routine to better adapt to treatment.
Some report experimenting with alternative medicine. Where
side-effects are severe and women are unable to manage them,
their treatment might be switched to another hormonal medi-
cine (extract 21). A range of life changes might also help man-
age the treatment side-effects. Women report specific coping
techniques too that ease the experience (extract 22).
Consequences Despite the difficulties, women attempt to ad-
here to their treatment plan, keeping in sight the end of treat-
ment, committing if only to avoid future regrets. On occa-
sions, some feel that skipping doses would be harmless, espe-
cially when side-effects become severe (extract 23). Women
report surprise at the severity of side-effects which can even
stop their social activities (extract 24). Women who take other
medication or are older report difficulty distinguishing the
exact cause of their symptoms, the different factors becoming
entangled (extract 25). Sometimes women forget if they have
taken their day’s dose which happens especially if there is a
change in their routine (extract 26). The downside is that for
some, the long-term nature of ET allows the presence of breast
cancer to linger on, even if just at a psychological level (ex-
tract 27).
Mediating factorsWomen’s ability to adapt to the side-effects
of treatment, receiving support throughout the treatment, and
knowledge about the treatment facilitate or constrain the pro-
cess of adhering long-term to the ET.
Category 3: taking a chance – stopping the treatment
early
Women are expected to adhere to their ET for a duration of at
least 5 years. However, some decide to stop early having taken
the medication for a shorter time (see Table 3).
Support Care Cancer
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Causal conditions The most quoted reason for stopping treat-
ment early is the severity of the side-effects (extract 28), which
can greatly impact women’s quality of life, compelling them
to reflect on their priorities. Living longer stops being the main
concern with a more contented life free of side-effects pre-
ferred even if it is shorter. For some, initial doubts about the
medication grow to overshadow any potential for benefit, es-
pecially if faced with obstacles or encouraged by others to
give up. Some report their healthcare provider giving them a
clear choice to stop, with others reporting their ambivalence.
Some cite lack of support during the treatment as the reason
for stopping prematurely, while others do it because they stop
trusting their healthcare provider or the entire healthcare ma-
chinery. Some also reason that having taken the medication
for a while would have conferred sufficient cover, negating
the need for further doses (extract 29). Belief in the healing
power of god, versus modern medicine, was also cited in the
data, albeit less frequently (extract 30).
Actions/interactions The decision to stop treatment early
might be made jointly by the woman and her healthcare pro-
vider, or she might decide to stop ET without discussing it
formally (extract 31). Ultimately, the action here is to perma-
nently stop taking the ET.
Consequences Feeling empowered to stop, women believe
that taking the treatment is no longer necessary and does not
justify the side-effects. This is not a choice they would have
anticipated at the start but arises because of their experience
with the medication, revealing to them that living longer is not
what matters anymore (extract 32). Stopping treatment early
leaves women feeling better in themselves, happier, more en-
ergetic and like ‘their old selves’. Their quality of life im-
proves greatly and their sense of normalcy returns (extract 33).
Mediating factors Quality of life taking precedence over lon-
gevity of life, beliefs about the treatment necessity and a con-
tinuous search of normalcy facilitate or constrain the process
of stopping ET early.
Discussion
Previous studies have documented the extent of non-
adherence to ET in breast cancer survivors despite the docu-
mented risks [25–29]. Much of that literature considers med-
ication adherence from a biomedical standpoint, seeing non-
adherence as a ‘challenge’ that needs to be tackled, for exam-
ple, with the use of an ‘intervention’ [14]. In contrast, this
paper focussed on collating the experiences of women pre-
scribed ET to help explain non-adherence and discontinuation
using, as much as possible, an ‘insider’ perspective. The rate
of publication of qualitative studies (which largely look for theTa
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insider perspective) in this area has increased sharply, with 17
studies of the 24 included in this review having been pub-
lished in the last 5 years. However, to the authors’ knowledge,
this is the first to synthesize the qualitative literature and de-
velop a theoretical understanding of women’s non-adherence
to long-term ET for breast cancer using GT. The theory de-
veloped helps explain why, having committed to taking ta-
moxifen or an aromatase inhibitor, adherence decreases over
time, and importantly, it shows the decision to cease treatment
early as an active choice that is made with a credible rationale.
Health professionals can use these findings to support women
via client-centred approaches.
Our study illustrates the importance of knowledge and support
to women at the different stages of the treatment. It suggests that
empowering women with knowledge about the treatment and
setting appropriate expectations beforehand, especially about
the side-effects, could help improve their experience of taking
ET. An educational tool for use throughout the treatment, for
example, could help probe for and address a range of issues that
might not otherwise be addressed. Specifically, knowledge about
the treatment itself, why it is needed and the range of side-effects
that might be encountered could be discussed and explored. The
authors are in the process of developing such a tool, using pic-
tograms and icons to visually represent each of the three para-
digmmodels, with the view to helping women reflect on specific
topics before, during and after medical consultations. For exam-
ple, visually showing the range of possible side-effects, and the
range of coping strategies, could help women prepare for the
side-effects in advance of treatment start. The shift in responsi-
bility as women begin taking ET and the dwindling professional
support available to them has been recognized elsewhere [30]
and is worth highlighting. This is especially important when
access to specialists and oncologists is withdrawn and other
healthcare professionals are seen by the women either to lack
expertise or the interest to provide support. A learning tool to
support the knowledge of non-specialist health professionals
might also prove helpful to women.
The current study is in coherence with the Necessity-
Concern Framework [31], which relates specifically to medi-
cation adherence and proposes that this behaviour is linked to
the balance of treatment concerns against beliefs about treat-
ment necessity. This ‘weighing up’ is in essence what breast
cancer survivors do according to the findings of the current
study. Women who think of adhering to ET as a Hobson’s
choice believe that the treatment is necessary and that adher-
ing to it will prevent cancer recurrence, no matter the severity
of side-effects. They are unlikely to entertain the idea of stop-
ping the treatment and try instead to take their medication
exactly as prescribed on a daily basis. On the other hand, those
with weaker beliefs about treatment necessity who experience
the side-effects, start accumulating concerns about the side-
effects, leaving them with the difficulty of the horned dilem-
ma. This congruence between the core category and the
Necessity-Concern Framework gives credibility to the current
study. The findings of this study are particularly useful as,
unlike the generic nature of the Necessity-Concern
Framework, the complex and dynamic models show the de-
tailed beliefs and experiences of women on ET.
A limitation of this study is the authors’ lack of access to the
original interview transcripts with the analysis built on the quotes
extracted by the original authors and their respective interpreta-
tions. Nonetheless, the model was based on 801 quotes, obtained
from 24 studies to reflect the experiences of 610 survivors of
breast cancer. The authors believe that this provided a sufficient
basis to develop a theoretical understanding within the context of
a qualitative meta-synthesis. As future work, an interview study
planned by the current authors and based on the categories in this
paper should allow a further examination of the theory for cur-
rency in a UK setting. As it stands, the current model provides a
basis for better informing survivors of breast cancer and health
professionals too about the challenges of medication taking be-
fore and during the treatment process.
Conclusion
The core category explained the difficulties women face with
the initial decision to accept long-term ET and then the every-
day challenge of continuing with the treatment or stopping it
prematurely. Designing an educational tool to inform survi-
vors and health care providers alike about the challenges for
women on ET could potentially improve other women’s ex-
perience on the treatment and in turn their adherence.
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